D I G I T A L D I A G N O S T I C S
The Hong Kong trial will be led by Professor Man-Fung Yuen – world-renowned hepatologist and Chair Professor of The University of Hong Kong and the Chief of the Division of Gastroenterology and Hepatology , Queen Mary Hospital , Hong Kong .
“ Over 257 million people are still living with chronic hepatitis B , and worldwide the disease disproportionately impacts Asian and Pacific Islander populations ,” said Dr Yuen .
“ While early screening and detection is still paramount , this novel epigenetic silencing approach offers new hope for clinicians and could make a major impact in these patient groups in particular .”
According to the World Health Organization , the burden of Hepatitis infection is highest in the Western Pacific Region – including China , Japan , Cambodia , New Zealand and Australia .
With a parallel clinical trial occurring in Auckland , New Zealand , Tune is focusing on countries that would see the most immediate impact and benefit from a new HBV treatment paradigm . Tune shared encouraging preclinical data in November 2024 demonstrating Tune-401 ’ s ability to repress both cccDNA and integrated DNA in target cells and animal models .
Armed with its innovative genetic tuning platform ( TEMPO ), Tune Therapeutics
64 www . intelligenthealth . tech